Pricing & Access· May 27, 2026 · 10 min readSpravato REMS and coverage guide: esketamine treatment-resistant depression documentation, site certification, buy-and-bill vs pharmacy handling, and payer prior authorizationSpravato (esketamine) CIII nasal spray is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation. This...By Ran Chen#REMS#Prior Authorization#Coverage Access
